SM
AERI

Sabby Management’s Aerie Pharmaceuticals AERI Stock Holding History

Sabby Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,726
Closed -$230K – 201
2017
Q3 		$230K Buy
+4,726
New +$258K 0.02% 124

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's AERI Position: Q4 2017 in Review

Sabby Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2017, closing a stake of 4,726 shares — an estimated $230K sold.

Sabby Management first reported a position in AERI in Q3 2017 and held it in 1 quarter. The position peaked at $230K in Q3 2017. 179 funds tracked by Wall St. Rank hold AERI as of Q4 2017.

  • Sabby Management reported no remaining Aerie Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sabby Management sold 4,726 Aerie Pharmaceuticals shares in Q4 2017, an estimated $230K.
  • Sabby Management first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Sabby Management's Aerie Pharmaceuticals position peaked at $230K in Q3 2017.
  • 179 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.